VistaGen Therapeutics, Inc.
VTGN
$3.60
-$0.83-18.74%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -57.30% | -68.05% | -75.12% | -47.51% | -11.52% |
| Total Depreciation and Amortization | 13.88% | 12.59% | 11.80% | 10.22% | 9.10% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 12.99% | 29.67% | 79.43% | -37.83% | -48.71% |
| Change in Net Operating Assets | 116.60% | 38.93% | 500.25% | 760.63% | 186.57% |
| Cash from Operations | -58.11% | -73.92% | -63.08% | -48.36% | -6.35% |
| Capital Expenditure | -29.88% | -107.77% | -213.11% | -312.50% | -1,212.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 95.71% | -52.17% | -- | -- | -- |
| Cash from Investing | 94.16% | -53.20% | -21,454.10% | -2,347.14% | -2,363.27% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -36,500.00% | 88.52% | -- | 100.00% | 100.06% |
| Issuance of Common Stock | -66.31% | -97.17% | -97.53% | -99.03% | 160.29% |
| Repurchase of Common Stock | -- | -- | -- | -75,900.00% | -75,900.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -65.47% | -96.39% | -97.50% | -99.32% | 172.02% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -146.01% | -157.81% | -150.75% | -151.07% | 1,909.31% |